REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it has been awarded a 2-year, $3.4 million grant from the United States Department of Defense1 to develop technology to advance vaccine research and development. Under the grant, Maxygen will continue development of ParallelaVax™ technology for rapid generation of vaccine candidates and high-throughput testing in animal models. The work will be done in collaboration with Aldevron LLC.
